TrialSignal transduction and targeted therapy2024

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial).

Hongtao Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.